FDA approves updated Covid-19 vaccines
The US FDA has approved updated COVID-19 vaccines as flu cases rise. The CDC recommends vaccination for adults 18 and older and immunocompromised children aged 6 months to 17 years. Medical experts advise immediate vaccination against both flu and COVID-19 to prevent severe illness and complications. Updated vaccines are available for the 2026-27 season.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The CDC advises vaccination for adults 18 and older and immunocompromised children aged 6 months to 17 years.
- ✓ Medical experts recommend immediate vaccination against both flu and COVID-19 to prevent severe illness and complications.
- ✓ Updated COVID-19 vaccines are available for the 2026-27 season.
What changed
The FDA's approval of updated COVID-19 vaccines for the 2026-27 season is the latest development.
Live updates
-
FDA Approves Updated COVID-19 Vaccines Amid Rising Flu Cases
The US FDA has approved updated COVID-19 vaccines as flu cases rise. The CDC recommends vaccination for adults 18 and older and immunocompromised children aged 6 months to 17 years. Medical experts advise immediate vaccination against both flu and COVID-19 to prevent severe illness and complications. Updated vaccines are available for the 2026-27 season.
Why it matters
The approval of updated COVID-19 vaccines comes as the US experiences a rise in flu cases. Vaccination is crucial to prevent severe illness and complications from both flu and COVID-19. The CDC provides guidelines for vaccination, and medical experts stress the importance of protection against both diseases.
What is confirmed
- The CDC advises vaccination for adults 18 and older and immunocompromised children aged 6 months to 17 years.
- Medical experts recommend immediate vaccination against both flu and COVID-19 to prevent severe illness and complications.
- Updated COVID-19 vaccines are available for the 2026-27 season.
Still unconfirmed
- Some public health tools like Vaccines.gov are reportedly non-functional.
What to watch next
- CDC guidance on vaccine distribution and public access
- efficacy rates of the updated COVID-19 vaccines
- uptake of vaccinations among high-risk groups
confidence 85%Sources used for this update (9)
- www.ajmc.com — A Timeline of COVID-19 Developments in 2020 | AJMC
- www.cdc.gov — Benefits of Getting Vaccinated | Covid | CDC
- www.fool.com — Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026? | The Motley Fool
- www.ideastream.org — Here’s why experts say now is an ideal time to protect yourself from flu | Ideastream Public Media
- katiecouric.com — Flu Shot 2026: When to Get It, Types of Vaccines
- www.wral.com — Coronavirus News and Reporting Coverage, page 6 | WRAL
- www.miragenews.com — Your Guide To Flu And Covid Vaccines At UC Davis Health
- www.timothysykes.com — MRNA Stock Builds Momentum Ahead Of Nasdaq-100 Debut
- www.marketscreener.com — BofA Adjusts Price Target on Novavax to $8 From $7, Keeps Underperform Rating
-
FDA Approves Updated Covid-19 Vaccines as Flu Season Nears
The US FDA has approved updated Covid-19 vaccines amid rising flu cases. Medical experts recommend immediate vaccination against both flu and COVID-19 to prevent severe illness and complications. The CDC advises vaccination for adults 18 and older and immunocompromised children aged 6 months to 17 years. However, some public health tools like Vaccines.gov are reportedly non-functional.
Why it matters
The approval and recommendations come as the US enters flu season, with health authorities warning of an early start in some western regions. The CDC's vaccination guidelines aim to protect vulnerable populations and prevent the spread of respiratory diseases. The situation is complicated by ongoing legal actions and policy shifts within the Health Department.
What is confirmed
- Getting vaccinated is the best way to reduce your risk of severe illness and complications from the flu.
- Experts say now is an ideal time to get a flu shot, before influenza starts spreading widely.
- The number of people sick with flu is starting to increase across the United States.
Still unconfirmed
- Some public tools like Vaccines.gov are reportedly non-functional.
What to watch next
- The effectiveness of the updated Covid-19 vaccines against new variants.
- The impact of vaccination efforts on flu and COVID-19 case numbers.
- The resolution of disruptions to public health guidance and tools.
confidence 90%Sources used for this update (3)
- theconversation.com — Flu season is near – here’s a guide to available vaccines
- abc11.com — Here's why experts say now is an ideal time to protect yourself from flu - ABC11 Raleigh-Durham
- medicalxpress.com — Flu season is near—here's a guide to available vaccines
-
FDA Approves Novavax COVID-19 Vaccine Amid CDC Guidance Turmoil
The FDA has granted full approval to Novavax's COVID-19 vaccine, though the agency has limited its use. This occurs as the CDC reinstates vaccination recommendations for adults 18 and older and immunocompromised children aged 6 months to 17 years. However, the delivery of health guidance remains disrupted by legal actions and policy shifts under Health Secretary Robert F. Kennedy Jr. While medical experts urge immediate flu and COVID-19 vaccination to precede seasonal peaks, some public tools like Vaccines.gov are reportedly non-functional.
Why it matters
The U.S. vaccine infrastructure is currently strained by conflicts between the Department of Health and Human Services and established health agencies. This instability coincides with the start of the respiratory virus season. Guidance is being supplemented by independent medical groups to prevent public confusion.
What is confirmed
- The FDA granted full approval to the Novavax COVID-19 vaccine with limited use.
- The CDC recommends COVID-19 vaccination for all adults 18 and older and immunocompromised children 6 months to 17 years.
- Medical experts recommend receiving flu vaccinations in October before the virus spreads widely.
- Ontario began providing free flu and COVID-19 shots to high-risk individuals on September 28.
Still unconfirmed
- The Vaccines.gov tool for finding nearby pharmacies is not working.
- Health Secretary Robert F. Kennedy Jr.'s policy efforts and associated legal actions have disrupted health guidance systems.
- Invivyd is pursuing an accelerated-approval pathway for VYD2311, a monoclonal antibody to prevent COVID-19.
What to watch next
- FDA decision on Invivyd's VYD2311 accelerated approval
- Resolution of lawsuits affecting CDC vaccine recommendations
confidence 85%Sources used for this update (27)
- www.cdc.gov — Current Epidemic Trends (Based on Rt) | CFA: Modeling and Forecasting | CDC
- www.cdc.gov — Respiratory Illnesses Data Channel | Respiratory Illnesses | CDC
- www.thestar.com — Ontario is launching free flu and COVID-19 shots next week as vaccination rates decline
- pharmaphorum.com — FDA finally okays Novavax's COVID-19 jab, with restrictions
- www.cdc.gov — Staying Up to Date with COVID-19 Vaccines | Covid | CDC
- www.cidrap.umn.edu — Most Americans confused about RFK Jr’s stance on measles vaccine as views dim of his ability to rein in outbreaks
- www.healthandme.com — WHO Sets 2027 Flu Vaccine Strains; US States Can Now Order Free COVID Shots For Kids | Health and Me
- www.chicagotribune.com — CDC vaccine recommendations are at a standstill
- www.cnn.com — The first mRNA flu vaccine is now available for older adults. Here’s what to know
- www.ajmc.com — VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
- www.statnews.com — Invivyd’s pursuit of a Covid vaccine alternative gets a lift, but an FDA hurdle may await
- www.cidrap.umn.edu — Long COVID, disputing measles deaths, and newborns without RSV protection: The State of US Vaccine Policy
-
Doctors Push Updated Flu and COVID Vaccines to Combat Confusion
Leading United States medical groups issued joint vaccination guidelines on Wednesday to address updated flu and COVID-19 shots. The guidance aims to reduce public confusion driven by shifting advice from the Trump administration. Concurrently, health experts recommend receiving annual flu vaccines by late October because protection takes approximately two weeks to develop before seasonal activity peaks. Separately, the first messenger RNA flu vaccine has become available for older adults, widening options as the fall virus season begins.
Why it matters
The unified medical guidance follows recent FDA approvals for updated COVID-19 formulas targeting the XFG variant. State ordering protocols have commenced after minor procurement delays. These autumn vaccine pushes occur alongside broader health initiatives, including the commercial availability of new messenger RNA technology for older influenza patients.
What is confirmed
- Leading U.S. medical groups issued joint flu and COVID-19 vaccination guidelines on Wednesday.
- The guidance aims to ease confusion caused by the Trump administration's changing advice.
- Health experts recommend getting the annual flu vaccine by late October.
- Updated flu shots take about two weeks to provide protection before seasonal activity peaks.
- The first mRNA flu vaccine is now available for older adults.
What to watch next
- Monitor public uptake and adherence to the joint medical guidelines during the fall peak season.
- Track the commercial distribution and patient response to the newly available mRNA flu vaccine for older adults.
confidence 100%Sources used for this update (6)
- www.ibtimes.com.au — How Long Does the Flu Shot Last? What Health Experts Want You to Know Before Peak Flu Season This Fall
- www.wjcl.com — The first mRNA flu vaccine is now available for older adults. Here’s what to know
- www.texarkanagazette.com — Top U.S. doctors offer updated flu and COVID vaccine recommendations, aiming to ease confusion
- www.eastbaytimes.com — Election 2026: Who are the candidates running for California governor?
- www.hirunews.lk — The first mRNA flu vaccine is now available for older adults
- markets.ft.com — Pfizer Advances Today's Cancer Care and Tomorrow's Potential Breakthroughs at ESMO
-
CDC opens state ordering for updated Covid-19 vaccines
The Centers for Disease Control and Prevention has started state ordering for updated COVID-19 vaccines. This follows FDA approval of the Pfizer and BioNTech COMIRNATY XFG formula, which targets the XFG variant for adults and children aged 5 and older. The rollout occurred nearly one month after regulatory approval. Health departments previously attributed the delay to unfinished procurement decisions. These updates arrive as experts report rising coronavirus infections in various regions this fall and manufacturers pursue post-pandemic revenue.
Why it matters
The timing of vaccine distribution is critical to managing seasonal surges in infections. State-level procurement determines how quickly the public can access updated formulas. The XFG variant represents the current target for these specific regulatory approvals.
What is confirmed
- The FDA approved the Pfizer and BioNTech COMIRNATY XFG formula for adults and children aged 5 and older.
- The CDC opened state ordering for updated COVID-19 vaccines nearly one month after FDA approval.
What to watch next
- Data on infection rates for the fall season
- Updates on state-level vaccine distribution timelines
confidence 100%Sources used for this update (4)
- TribLIVE.com — Western Pennsylvania experts on what to know about this year’s flu season
- www.prnewswire.com — FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
- www.finanznachrichten.de — Eli Lilly and Company: FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
- pharmabiz.com — Rising life expectancy changed India’s health challenges: Dr Jitendra Singh
-
CDC Opens Vaccine Ordering After Delay as FDA Approves New Formulas
The Centers for Disease Control and Prevention has opened state ordering for updated COVID-19 vaccines nearly one month after Food and Drug Administration approval, following an unexplained delay that health departments previously blamed on unfinished procurement decisions. Meanwhile, Pfizer and BioNTech secured regulatory clearance for their COMIRNATY XFG formula targeting the XFG variant for adults and children aged 5 and older. Experts warn that coronavirus infections are increasing in many areas this fall, even as manufacturers seek post-pandemic revenue boosts from the new shots.
Why it matters
The rollout follows the FDA approval of updated COVID-19 vaccine formulas, including Pfizer and BioNTech's COMIRNATY XFG for individuals aged 5 to 64 and adults 65 and older. State health departments faced a nearly one-month delay in ordering free vaccines for vulnerable children while federal procurement decisions remained unfinished. The distribution snarl occurs as health experts warn the public that infections are rising across multiple regions.
What is confirmed
- The U.S. FDA approved the supplemental Biologics License Application for Pfizer and BioNTech's COMIRNATY XFG 2026-2027 COVID-19 vaccine formula on August 27.
- The CDC has opened up the process for states to order free vaccines for children nearly one month after the FDA approved updated COVID shots.
- Health departments previously blamed the vaccine ordering delay on not yet finalized procurement decisions.
Still unconfirmed
- Pfizer and BioNTech could receive a post-pandemic revenue boost from the new vaccine formula XFG.
What to watch next
- State distribution progress of the newly ordered COVID-19 vaccines to vulnerable children and adults.
- Infection rate trajectories as health experts track rising COVID-19 cases in multiple areas this fall.
confidence 95%Sources used for this update (5)
- finance.yahoo.com — Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost?
- newsable.asianetnews.com — From $63 To $195: Moderna’s Two-Month Rerating Isn’t Done
- arstechnica.com — CDC opens state ordering for COVID-19 vaccines after unexplained delay
- www.cidrap.umn.edu — CDC greenlights COVID vaccines for vulnerable children after nearly 1-month delay
- www.aol.com — Experts Warn COVID Cases Are 'Increasing In Many Areas' — But There's Good News Too
-
FDA Approves Updated Covid-19 Vaccines as Moderna Expands mRNA Pipeline
The FDA has approved updated Covid-19 vaccines, sparking a rise in Moderna shares between 13.31 percent and 14.21 percent. This approval coincides with positive Phase 3 oncology trial results for the company. While Moderna reported an annual revenue of $1.94 billion and a net loss of $2.82 billion, financial institutions have increased their confidence through capital-raising initiatives. Additionally, Moderna is advancing its mRNA technology into flu vaccinations, while health experts advise the public to get flu shots by mid-October for maximum efficacy.
Why it matters
Moderna is leveraging its mRNA platform to move beyond Covid-19 into oncology and influenza. This shift occurs as the company manages significant net losses despite high revenue. The timing aligns with seasonal public health pushes for flu prevention.
What is confirmed
- The FDA approved updated Covid-19 vaccines.
- Moderna shares rose between 13.31 percent and 14.21 percent.
- Moderna reported an annual revenue of $1.94 billion and a net loss of $2.82 billion.
What to watch next
- Clinical trial results for Moderna's mRNA flu shot
- Further Phase 3 oncology trial data
confidence 100%Sources used for this update (2)
- www.sciencenews.org — Moderna’s mRNA flu shot hits the target
- www.usatoday.com — Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
-
Moderna Stock Surges Following FDA Vaccine Approval
Moderna shares climbed between 13.31 percent and 14.21 percent following the federal approval of updated Covid-19 vaccines and positive Phase 3 oncology trial results. Financial institutions showed strengthened confidence backed by capital-raising initiatives, despite the company reporting an annual revenue of $1.94 billion and a net loss of $2.82 billion. Meanwhile, health experts recommend that individuals receive flu vaccinations by mid-October to ensure peak effectiveness ahead of the upcoming infection season.
Why it matters
The recent market rally for Moderna links commercial product authorizations with broader clinical developments in oncology. Regulatory clearances for updated seasonal immunizations arrive concurrently with targeted efforts by health authorities to encourage early autumn inoculations. These developments unfold as North American health systems prepare for concurrent respiratory virus threats.
What is confirmed
- Moderna Inc. stocks traded up by 13.31 percent after breakthrough vaccine data spurred investor optimism.
- Moderna stock rose due to positive Phase 3 oncology trial results and upcoming congress presentations.
- FDA approval of updated COVID-19 vaccines and capital-raising initiatives reinforced institutional financial confidence.
- Moderna reported annual revenue of $1.94 billion and a net loss of $2.82 billion.
Still unconfirmed
- Health experts issued updated flu vaccination guidance urging vaccination by mid-October for maximum effectiveness ahead of peak infection season.
What to watch next
- Upcoming medical congress presentations regarding Moderna Phase 3 oncology trials
- Mid-October vaccination milestones for seasonal flu and updated Covid-19 shots
confidence 90%Sources used for this update (3)
- www.wishtv.com — Health experts urge vaccination by mid-October for maximum effectiveness
- stockstotrade.com — Moderna Stock Surges As FDA Approval And Oncology Wins Fuel Rally
- www.tradingkey.com — Moderna Inc Stock (MRNA) Moved Up by 14.21% on Sep 21: Drivers Behind the Movement
-
FDA Approves 2026-27 Covid-19 Vaccines Amid Seasonal Health Pressures
The FDA has approved updated Covid-19 vaccines for the 2026-27 respiratory season. While these shots are available, the CDC reports a delay for uninsured children. In Canada, Health Canada authorized the Pfizer and BioNTech COMIRNATY vaccine for people aged 6 months and older to target the Omicron XFG lineage. These rollouts happen as the US and Canada face the start of flu season and a rise in US measles cases. An mRNA flu vaccine is also now available to expand protection options for older adults.
Why it matters
Annual vaccinations reduce risks of death, hospitalization, and severe influenza illness. Health officials are managing these rollouts alongside a concurrent increase in measles infections.
What is confirmed
- The FDA approved updated Covid-19 vaccines for the 2026-27 respiratory virus season.
- Health Canada authorized the Pfizer and BioNTech COMIRNATY vaccine for individuals aged 6 months and older.
- The COMIRNATY vaccine is adapted for the Omicron XFG lineage.
- CDC reports a delay in vaccine availability for uninsured children.
Still unconfirmed
- HHS Secretary Robert F. Kennedy Jr. is described as anti-vaccine.
What to watch next
- Resolution of vaccine delays for uninsured children
- Measles case trends in the United States
- Flu season hospitalization rates for older adults using mRNA vaccines
confidence 90%Sources used for this update (2)
- www.news-medical.net — New mRNA vaccine expands flu protection options for older adults
- www.yahoo.com — RFK Jr. goes rabidly anti-vaccine in face of measles outbreak | Opinion
-
FDA Approves Updated COVID-19 Vaccines for 2026-27 Season
The FDA approved updated COVID-19 vaccines for the 2026-27 respiratory virus season. While these vaccines are available, the CDC reports a delay for uninsured children. In Canada, Health Canada authorized the Pfizer and BioNTech COMIRNATY vaccine, adapted for the Omicron XFG lineage, for individuals aged 6 months and older. These rollouts occur as health officials in the US and Canada manage seasonal respiratory illnesses, coinciding with the start of the flu season and an increase in measles cases within the United States.
Why it matters
Seasonal vaccine updates target evolving viral lineages to maintain immunity across populations. The simultaneous rise of flu and measles complicates public health efforts during the autumn respiratory surge. Coordination between US and Canadian regulators ensures broad access to adapted boosters.
What is confirmed
- The FDA approved updated COVID-19 vaccines for the 2026-27 respiratory virus season.
- Health Canada authorized the Pfizer and BioNTech COMIRNATY vaccine adapted for the Omicron XFG lineage for people aged 6 months and older.
Still unconfirmed
- Dr. Daniel Griffin warned that four measles deaths in one state demonstrate the cost of gutting vaccine defaults.
What to watch next
- CDC updates on vaccine access for uninsured children
- Public health reports on measles death tolls by state
confidence 90%Sources used for this update (2)
- www.usatoday.com — What's going on with COVID? The latest on strains, cases, symptoms.
- finance.biggo.com — Griffin: Four Measles Deaths in One State Show the Cost of Gutting Vaccine Defaults
-
FDA approves updated Covid-19 vaccines for 2026-27 season
The Food and Drug Administration approved updated COVID-19 vaccines for the 2026-27 respiratory virus season. While the vaccines are available, the CDC reports a delay for uninsured children. This rollout occurs as health officials in the US and Canada manage seasonal respiratory illnesses. In Canada, Health Canada authorized the Pfizer and BioNTech COMIRNATY vaccine adapted for the Omicron XFG lineage for people aged 6 months and older. This effort coincides with the start of the flu season and rising measles cases in the United States.
Why it matters
Annual vaccine updates target evolving viral strains to maintain immunity during winter surges. The current cycle includes preparations for flu and RSV alongside COVID-19. Public health officials are balancing these rollouts against fluctuating infection rates and varying access for uninsured populations.
What is confirmed
- The FDA approved updated COVID-19 vaccines for the 2026-27 respiratory virus season.
- Health Canada authorized the Pfizer and BioNTech COMIRNATY vaccine adapted for the Omicron XFG lineage for individuals aged 6 months and older.
Still unconfirmed
- Measles cases in the US are at their highest levels seen in decades.
What to watch next
- CDC resolution regarding vaccine access for uninsured children
- Hospitalization data for the 2026-27 respiratory season
confidence 90%Sources used for this update (5)
- westchester.news12.com — Updated COVID-19 vaccine delayed for uninsured children, CDC says
- www.wafb.com — Doctors urge flu shots as season begins in Baton Rouge
- www.fool.com — Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
- finance.yahoo.com — Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock?
- truthout.org — “You Have a Strong and Steadfast Friend,” RFK Jr. Tells Anti-Vaxxers
-
Health Canada authorizes Omicron XFG-adapted vaccine for 2026-2027 season
Health Canada authorized the Pfizer and BioNTech COMIRNATY vaccine adapted for the Omicron XFG lineage. The authorization applies to individuals aged 6 months and older. This rollout aligns with public health recommendations for the 2026-2027 season. Current rates of seasonal respiratory illnesses are low but increasing. This follows similar vaccine distribution efforts in the United States, where officials are managing rising infections and hospitalizations alongside preparations for flu and RSV seasons.
Why it matters
The XFG-adapted vaccine targets a specific Omicron lineage to maintain immunity against evolving variants. Global health agencies are coordinating these updates as respiratory viral threats typically increase during the fall.
What is confirmed
- Health Canada authorized the Pfizer and BioNTech COMIRNATY vaccine adapted for the Omicron XFG lineage for individuals aged 6 months and older.
- Seasonal respiratory illness rates are currently low but increasing.
Still unconfirmed
- A top defense official stated that the benefits of COVID-19 vaccines outweighed the risks after learning of post-vaccination heart inflammation in early 2021.
What to watch next
- FDA approval status for the XFG-adapted vaccine in the US
- Updated hospitalization data for New York City and other US hubs
confidence 100%Sources used for this update (3)
- www.theepochtimes.com — Top Defense Official Learned of Post-Vaccination Heart Inflammation in Early 2021
- ca.finance.yahoo.com — Health Canada Authorizes Pfizer and BioNTech's Omicron XFG-Adapted COVID-19 Vaccine
- www.bostonglobe.com — What you need to know about this year’s fall vaccines
-
Oregon expands access to updated Covid-19 vaccines
Oregon has issued a statewide order providing broad access to updated Covid-19 vaccines as the fall respiratory season begins. This follows FDA approval and the start of vaccine distribution in Florida and the Bay Area. The rollout happens amid rising infections and hospitalizations in the U.S., including New York City, where weekly admissions topped 500 in early September. Health officials are coordinating these efforts alongside preparations for flu and RSV seasons to manage the increase in respiratory viral threats.
Why it matters
The current push for vaccinations follows the highest New York City admission levels since October 2025. Regional hotspots in Pennsylvania, specifically Bucks and Montgomery counties, report infection rates well above the state average.
What is confirmed
- Oregon issued a statewide order allowing broad access to updated Covid-19 vaccines.
- New York City reported over 500 weekly admissions in early September.
- The FDA expects updated Covid-19 vaccines to reach hospitals, clinics, and doctors offices later in September.
What to watch next
- Arrival of vaccines in remaining U.S. medical facilities
- Updated infection rate data from Bucks and Montgomery counties
confidence 90%Sources used for this update (5)
- www.usatoday.com — Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48 ...
- www.grantspasstribune.com — Oregon Clears Updated COVID Vaccines for Broad Access Ahead of Fall Respiratory Season
- markets.businessinsider.com — A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- www.miragenews.com — What You Need To Know About Flu, COVID, And RSV Season
- www.cidrap.umn.edu — Vaccine Integrity Project turns its eye to meningococcal and pneumococcal vaccines
-
FDA expects updated Covid-19 vaccines in clinics later this month
The FDA expects updated Covid-19 vaccines to arrive in hospitals, clinics, and doctors offices later in September. Distribution has already begun in Florida and the Bay Area. This rollout coincides with a national increase in infections and hospitalizations. New York City reported over 500 weekly admissions in early September, the highest level since October 2025. In Pennsylvania, the Health Department reports that Bucks and Montgomery counties are seeing infection rates significantly above the state average. Meanwhile, China has approved a JN.1-targeted mRNA vaccine from Walvax for adults.
Why it matters
Respiratory illness trends are growing across the United States according to the CDC. Local health departments in New York have already diverged from federal guidance by endorsing updated vaccines for all adults.
What is confirmed
- The FDA expects updated Covid-19 vaccines in doctors offices, hospitals, and clinics later this month.
- Updated Covid-19 and flu vaccines are available to the public in Florida and the Bay Area.
- China approved Walvax's mRNA Covid-19 vaccine targeting the Omicron JN.1 strain for adults.
Still unconfirmed
- New York City logged over 500 Covid-19 hospital admissions in early September 2026.
- Bucks County weekly new Covid-19 cases range from 15 to 20 per 100,000 residents.
- Montgomery County weekly new Covid-19 cases range from 12 to 18 per 100,000 residents.
What to watch next
- Arrival of updated vaccines in remaining US medical facilities by the end of September
- Updated hospitalization data from the Pennsylvania Health Department
confidence 90%Sources used for this update (6)
- www.thereporteronline.com — Bucks County outpacing average for new COVID infections
- news.europawire.eu — Takeda’s Zasocitinib Receives FDA Priority Review for Moderate-to-Severe Plaque Psoriasis Following Positive Phase 3 Results in Nearly 3,000 Patients
- www.sun-sentinel.com — Get ready for flu season: Florida pharmacies rolling out new mRNA vaccines and updated COVID shots
- allsci.com — China approves Walvax’s third mRNA COVID-19 vaccine, targeting the Omicron JN.1 strain
- hoodline.com — NYC COVID Hospitalizations Hit 500 in a Week, Officials Push Fall Shots
- www.afp.com — U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment ...
-
New York Health Departments Endorse Covid-19 Vaccines for All Adults
New York State and city health departments are endorsing the recommendations of medical societies to support updated Covid-19 vaccines for all adults, breaking with federal guidance. Meanwhile, health officials confirm that updated Covid-19 and flu vaccines are currently available to the public in regions such as the Bay Area. This rollout arrives during a late-summer rise in virus cases across the United States. Concurrently, medical groups including the American Medical Association and the Vaccine Integrity Project have released independent science-based respiratory vaccine guidance.
Why it matters
The divergence between local health department endorsements and federal policy highlights ongoing debates regarding universal vaccine eligibility. Medical organizations are stepping in to issue independent guidance as public health agencies handle the autumn immunization schedule. These developments follow the Food and Drug Administration's August approvals, which included 13 new drugs and expanded indications.
What is confirmed
- New York State and city health departments are endorsing the recommendations of medical societies to support the vaccine for all adults.
- The American Medical Association and the Vaccine Integrity Project spearhead their own vaccine guidelines.
What to watch next
- Whether additional state or local health departments will break with federal vaccine recommendations
- Uptake rates for the newly available Covid-19 and flu vaccines across different regions
confidence 90%Sources used for this update (4)
- www.newsday.com — Vaccine for COVID-19 endorsed by New York State and city health departments for all adults, breaking with federal government
- www.deseret.com — Medical groups issue ‘science-based’ respiratory vaccine guidance
- www.rttnews.com — New FDA Drug Approvals - August 2026
- www.mercurynews.com — COVID-19, flu vaccines are available in the Bay Area. Here’s how to get them.
-
Updated 2026-27 COVID-19 Vaccines Roll Out Amid Rising Late-Summer Cases
Updated COVID-19 vaccines for the 2026-27 season are now available to the public, with rollouts currently underway in California. The arrival of these doses coincides with a late-summer surge in cases across the United States, particularly in Texas. Sanofi has launched the "Serve Up Protection" campaign with USA Pickleball to promote NUVAXOVID, the only FDA-approved protein-based, non-mRNA option. This vaccine targets adults 65 and older and high-risk individuals aged 12 to 64. These efforts follow recent FDA approvals for Pfizer/BioNTech, Moderna, and Novavax vaccines targeting the XFG variant.
Why it matters
The rollout follows a period of instability at the FDA, which the Trump administration addressed by filling four senior leadership positions. State officials in New Mexico previously urged vaccination despite federal policy shifts. This coincides with the approval of Moderna's mFLUSIVA mRNA influenza vaccine.
What is confirmed
- The 2026-27 updated COVID-19 vaccine is rolling out across California.
- Sanofi and USA Pickleball launched the "Serve Up Protection" campaign to educate older adults about NUVAXOVID.
- NUVAXOVID is the only FDA-approved protein-based, non-mRNA COVID-19 vaccine.
- NUVAXOVID is approved for adults aged 65 and older and high-risk individuals aged 12 to 64.
Still unconfirmed
- COVID-19 cases are rising across the country, specifically in Texas.
What to watch next
- Data on the efficacy of XFG-targeted vaccines against current late-summer strains
- Insurance coverage details for the 2026-27 rollout across different US states
confidence 95%Sources used for this update (5)
- www.galvnews.com — As Covid rises, fall vaccines arrive
- finance.yahoo.com — Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID™
- www.kqed.org — A New COVID Vaccine Is Here (Without Much Fanfare). When Should You Get It?
- www.rttnews.com — Sanofi Partners With USA Pickleball On COVID-19 Protection Campaign
- markets.businessinsider.com — Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
-
FDA approves updated XFG COVID-19 vaccines amid leadership shifts
The FDA approved updated COVID-19 vaccines from Pfizer/BioNTech, Moderna, and Novavax targeting the XFG variant for vulnerable populations for the 2026-2027 season. These approvals coincide with the Trump administration filling four senior roles at the agency, including top officials for vaccines and drugs, to stabilize the organization after months of upheaval. Local health experts report COVID-19 cases are rising across all age groups, prompting state officials in New Mexico to recommend current vaccines despite federal policy fluctuations. This rollout occurs alongside the approval of Moderna's mFLUSIVA mRNA influenza vaccine.
Why it matters
The FDA has faced instability since March following the departure of the commissioner and senior directors. Medical organizations are now issuing independent guidelines because the CDC advisory group has not provided seasonal shot recommendations.
What is confirmed
- The FDA approved 2026-2027 COVID-19 vaccine formulations from Pfizer/BioNTech, Moderna, and Novavax targeting the XFG variant.
- The Trump administration named four officials to senior roles at the FDA, including top leaders for drugs and vaccines.
- The FDA has seen the departure of the commissioner and top officials for drugs and vaccines since March.
Still unconfirmed
- COVID-19 cases are increasing across all age groups according to University Health chief epidemiologist Dr. Jason Bowling.
- Moderna stock experienced a 133.7 percent gain in 30 days.
What to watch next
- Official seasonal vaccination recommendations from the CDC advisory group
- Implementation of the newly created FDA position on artificial intelligence and technology
confidence 90%Sources used for this update (7)
- www.dailynews.com — FDA fills four senior roles, including top officials for drugs, vaccines and tobacco
- www.ksat.com — COVID-19 cases on the rise across all age groups, local healthcare expert says
- arstechnica.com — What to know about COVID and flu shots as RFK Jr.’s chaos drags on
- www.whec.com — FDA fills four senior roles, including top officials for drugs, vaccines and tobacco
- www.santafenewmexican.com — New Mexico health officials recommend latest COVID, flu vaccines despite federal changes
- www.vaccineadvisor.com — FDA Approves Updated 2026-2027 COVID-19 Vaccines
- www.newscase.com — Moderna’s 133% Monthly Surge Meets Wall Street’s Cold Water
-
FDA Approves Updated Covid-19 Vaccines
The Food and Drug Administration has approved four updated COVID-19 vaccines targeting the XFG variant for the 2026-2027 season alongside Moderna's mFLUSIVA, the first mRNA influenza vaccine. These regulatory decisions arrive as rising case numbers drive demand across the United States. In the absence of seasonal shot recommendations from the Centers for Disease Control and Prevention advisory group, leading medical organizations are issuing independent vaccination guidelines this fall. This physician-led strategy aims to minimize public confusion and streamline patient visits as cooler weather approaches.
Why it matters
Regulatory approvals for updated formulations typically guide seasonal public health campaigns. When federal advisory bodies delay or lack specific scheduling recommendations, professional medical groups step into the void to provide direction for providers and patients. Coordinating multiple immunizations during a single visit helps reduce administrative burdens and patient fatigue.
What is confirmed
- The FDA approved four updated COVID-19 vaccines for the 2026-2027 season to target the XFG variant.
- The FDA approved Moderna's mFLUSIVA, marking the first approval for an mRNA influenza vaccine.
- Leading U.S. medical groups are issuing independent autumn vaccination guidelines to reduce public confusion.
What to watch next
- Release of official vaccination recommendations from federal health advisory bodies
- Adoption rates of the newly approved vaccines among patients visiting medical clinics this fall
confidence 100%Sources used for this update (6)
- www.postandcourier.com — Editorial: Roll up your sleeve and save yourself the headache of multiple doctor visits
- www.clinicaltrialvanguard.com — The Algorithm Passed Every Benchmark. The Patients Didn’t Notice.
- pmlive.com — AstraZenca’s Etcamah combination therapy given FDA Accelerated Approval for breast cancer
- www.rttnews.com — ISpecimen In Focus, Genelux Nears Phase 3 Ovarian Cancer Data, Biofrontera Awaits FDA Decision
- finance.yahoo.com — Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand ...
- uk.finance.yahoo.com — UK’s MHRA Accepts Biosplice’s Application for Lorecivivint (LOR) in Knee Osteoarthritis and Begins Assessment
-
FDA Approves Four Updated COVID-19 Vaccines for 2026-2027 Season
The FDA has approved four updated COVID-19 vaccines for the 2026-2027 season to combat rising cases across the United States. These vaccines target the XFG variant. In a separate development, the FDA granted approval for Moderna's mFLUSIVA, the first mRNA influenza vaccine. While the FDA has cleared these products, leading U.S. medical groups are issuing their own vaccination guidelines this fall to reduce public confusion. These doctors are stepping in because seasonal shot recommendations from the CDC advisory group are currently lacking.
Why it matters
Public health officials are managing a transition in how vaccine recommendations are communicated under the Trump administration. The timing coincides with regional spikes in COVID-19 cases in states like Illinois and Colorado. Clear guidance is necessary to encourage simultaneous uptake of flu and COVID-19 shots.
What is confirmed
- The FDA approved four updated COVID-19 vaccines for the 2026-2027 season.
- The updated COVID-19 vaccines target the XFG variant.
- Leading U.S. medical groups are urging the public to receive updated flu and COVID-19 vaccinations this fall.
- Moderna's mFLUSIVA is the first FDA-approved mRNA influenza vaccine.
Still unconfirmed
- The CDC advisory group has been sidelined regarding seasonal shot recommendations.
What to watch next
- Official CDC guidelines for the 2026-2027 respiratory season
- Distribution data for the mFLUSIVA mRNA flu vaccine
- Updates on COVID-19 case trends in Colorado and Illinois
confidence 90%Sources used for this update (8)
- www.timesleader.com — Top US doctors offer updated flu and COVID vaccine recommendations, aiming to ease confusion
- www.healthline.com — FDA Approves 4 Updated COVID-19 Vaccines for 2026–2027 Season
- uk.finance.yahoo.com — Citi backs AstraZeneca sentiment boost after Etcamah wins accelerated FDA approval
- pmlive.com — Abivax has appointed James Berger as Global Head of Marketing
- www.pharmabiz.com — Piyush Goyal calls for resilient pharma supply chains, global investment and stronger R&D
- www.findarticles.com — FDA Approves Moderna’s First mRNA Flu Vaccine
- www.yahoo.com — With CDC advisory group sidelined and seasonal shot recommendations lacking, doctors step in
- uk.finance.yahoo.com — Unlocking Opportunity: Dominate the Market of CAR/TCR/TIL Therapies in Oncology with Confidence. See Exactly How Gilead, Cellectis, MediGene, GenScript, and CARsgen Are ...
-
FDA Approves 2026-2027 Covid-19 Vaccines as Regional Cases Rise
The FDA approved the 2026-2027 Pfizer and BioNTech vaccine targeting the XFG variant to match circulating strains. Current approvals prioritize people with underlying health conditions and adults aged 65 and older. Medical organizations are urging the public to receive updated flu and COVID-19 shots this fall to resolve confusion over federal policies. While CDC data shows rising cases in Illinois, Colorado is experiencing a COVID bump that may be a late summer peak or an early start to the winter respiratory season. Colorado has extended a statewide standing prescription to allow pharmacists to dispense vaccines.
Why it matters
Respiratory virus trends vary by region, complicating the timing of booster shots for the general public. Federal guidelines aim to provide science-based advice to stabilize public health responses. The shift toward pharmacist-led distribution in some states reflects efforts to increase vaccine accessibility.
What is confirmed
- The FDA approved the 2026-2027 Pfizer and BioNTech vaccine targeting the XFG variant.
- Current vaccine approvals prioritize adults aged 65 and older and individuals with underlying health conditions.
Still unconfirmed
- Colorado is seeing either a later-than-usual COVID-19 bump or an earlier-than-expected start to the fall and winter respiratory season.
- COVID cases are trending upwards in Illinois.
What to watch next
- Expansion of FDA approvals to younger age groups
- CDC reports on the national prevalence of the XFG variant
- Additional states implementing standing prescriptions for pharmacists
confidence 90%Sources used for this update (7)
- www.reporterherald.com — Colorado is seeing a COVID bump. Should you get the booster now?
- www.cidrap.umn.edu — HPV vaccine uptake in US teens hasn’t increased in 4 years
- coloradosun.com — Colorado just made it easier to get a COVID vaccine this year
- TribLIVE.com — Western Pa. docs offer advice on staying healthy with kids back in school
- hayspost.com — Doctors offer updated flu and COVID vaccine recommendations, aiming to ease confusion
- www.wxow.com — 6-week-old infant died of measles, Pennsylvania county coroner says
- bangaloremirror.indiatimes.com — Silent pain
-
U.S. Medical Groups Issue Fall Vaccine Guidelines Amid Rising COVID Cases
Leading U.S. medical organizations issued new guidelines Wednesday urging the public to receive updated flu and COVID-19 vaccinations this fall. These recommendations aim to resolve confusion stemming from shifting federal policies and provide science-based advice. The FDA has approved the 2026-2027 Pfizer and BioNTech vaccine, which targets the XFG variant to match current circulating strains. This push comes as CDC data indicates COVID cases are already trending upwards in Illinois. Current approvals prioritize adults aged 65 and older and people with underlying health conditions.
Why it matters
Medical societies are stepping in to provide clarity that they believe is missing from federal guidance. This effort follows a period where some families experienced vaccine shortages because older versions were removed before new ones arrived. The timing coincides with the start of the annual cold and flu season.
What is confirmed
- The FDA approved the Pfizer and BioNTech 2026-2027 COVID-19 vaccine targeting the XFG variant.
- Leading U.S. medical groups are urging the public to get updated flu and COVID-19 vaccinations this fall.
- CDC data shows COVID cases are trending upwards in Illinois.
- Medical societies issued new guidelines to address confusion caused by shifting federal policies.
Still unconfirmed
- Moderna's updated mRNA vaccine has been approved by the MHRA for the 2026/27 NHS programme.
What to watch next
- FDA approval status for Moderna's updated 2026-2027 vaccine in the U.S.
- Updates on vaccine availability for families facing gaps in supply.
- CDC official guidance updates regarding the XFG variant.
confidence 90%Sources used for this update (9)
- www.ibtimes.com.au — Top Doctors Issue New Flu And COVID Vaccine Guidance For Fall, Aiming To Cut Through Federal Confusion
- www.nbcdfw.com — Top U.S. doctors offer updated flu and COVID vaccine recommendations
- www.nbcchicago.com — Fall vaccines: Latest Covid, flu RSV vaccine recommendations as some cases rise
- www.miamitimesonline.com — Top US doctors offer updated flu and COVID vaccine recommendations, aiming to ease confusion
- pmlive.com — Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine approved by US FDA
- pmlive.com — Moderna’s updated COVID-19 mRNA vaccine approved by MHRA
- www.healio.com — Physicians publish fall vaccine guidance, filling void left by CDC
- uk.finance.yahoo.com — Pfizer (PFE) Stock Looks Fully Valued As Earnings Run Ahead Of Value
- www.sentinelandenterprise.com — Editorial: Tailored vaccines a shot in the arm against flu, COVID
-
Medical groups urge fall vaccinations as FDA-approved COVID shots roll out
Leading U.S. medical organizations, including the AMA, AAFP, and IDSA, are urging Americans to receive updated flu and COVID-19 vaccinations this fall. These guidelines aim to reduce confusion regarding the science and timing of the shots. While the FDA has approved new vaccines for the 2026-2027 season, some families are facing a gap in availability because older vaccine versions were removed from shelves before the new rollouts arrived. Current approvals target adults 65 and older and individuals with underlying health conditions to combat the XFG variant.
Why it matters
The 2026-2027 vaccine cycle focuses on the dominant XFG variant. Case numbers are currently rising in Bexar County and Kansas City, though they remain lower than in previous years. Coordination between medical groups is intended to streamline the simultaneous rollout of flu and COVID-19 shots.
What is confirmed
- Leading U.S. medical organizations are urging people to get updated flu and COVID-19 vaccinations this fall.
- The AMA, AAFP, and IDSA are issuing guidelines and highlighting the science behind the recommendations.
Still unconfirmed
- The removal of old vaccine shots from shelves has created an availability gap for families waiting for new rollouts.
What to watch next
- Insurance coverage determinations for the updated fall COVID-19 vaccines.
- Expansion of FDA approval beyond adults 65 and those with underlying conditions.
confidence 90%Sources used for this update (5)
- www.wyff4.com — New COVID-19 vaccine rolls out after FDA approval prompts availability gap
- www.ocregister.com — Top US doctors offer updated flu and COVID vaccine recommendations, aiming to ease confusion
- www.medpagetoday.com — Doctors Groups Offer Updated Flu, COVID Vaccine Recs to Ease Confusion
- www.fox5atlanta.com — Doctors, experts issue updated advice on flu, COVID shots: What to know
- www.aol.com — Updated COVID-19 vaccines are coming this fall. Will insurance cover them?
-
FDA approves 2026-2027 COVID-19 vaccines targeting XFG variant
The FDA has approved updated COVID-19 vaccines for the 2026-2027 season to target the dominant XFG variant. Approved products include Spikevax and mNEXSPIKE from Moderna, Nuvaxovid from Sanofi, and formulations from Pfizer-BioNTech. Current approvals focus on adults 65 and older and those with underlying health conditions. While case numbers are climbing in areas like Kansas City and Bexar County, they remain below levels seen in previous years. Mayo Clinic issued guidance on August 28 regarding who should receive the updated doses this fall.
Why it matters
These updates coincide with students returning to school, a period that typically triggers surges in respiratory infections. The XFG Stratus variant is the primary target for this season's formulations. Manufacturers are distributing doses to pharmacies and hospitals as regional case trends shift.
What is confirmed
- The FDA approved updated COVID-19 vaccines for the 2026-2027 season targeting the XFG variant.
- Approved vaccines include products from Moderna, Pfizer-BioNTech, and Sanofi.
- Mayo Clinic issued guidance on August 28 regarding the updated fall vaccine.
Still unconfirmed
- The FDA released Pfizer from commitments made during its last COVID vaccine approval.
- Moderna stock rose 156% in August.
What to watch next
- Clarification on insurance coverage for low-risk individuals
- Clinical trial results for Invivyd's VYD2311 studies
- Updated case numbers as school attendance increases nationwide
confidence 90%Sources used for this update (7)
- medicaldialogues.in — FDA Approves Updated COVID-19 Vaccines Targeting XFG Variant for 2026–2027
- www.kcur.org — As Kansas City kids go back to school, here's what to know about disease and vaccines
- www.yahoo.com — Mayo Clinic releases guidance for this year's COVID-19 vaccine
- www.usatoday.com — While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 ...
- www.insidermonkey.com — Moderna (MRNA) Soars 156% in August — Here’s What Propelled The Rally
- justthenews.com — From 'measles-associated' deaths to new COVID vaccines, doubts mount based on absence of evidence
- markets.businessinsider.com — Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
-
FDA Approves Updated COVID-19 Vaccines for 2026-27 Season
The FDA approved updated COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax-Sanofi to combat the XFG Stratus variant. Moderna's approved products include Spikevax and mNEXSPIKE, while Sanofi's approved vaccine is Nuvaxovid. Current approvals target adults 65 and older and individuals with underlying health conditions. These approvals come as COVID-19 cases rise in areas like Bexar County, coinciding with students returning to school. Manufacturers are shipping doses to hospitals and pharmacies, though insurance coverage for low-risk individuals remains uncertain.
Why it matters
The XFG Stratus variant is the current dominant strain driving a new wave of infections. This seasonal update follows a pattern of tailoring mRNA and protein-based vaccines to evolving subvariants. The timing aligns with a broader increase in respiratory illnesses as autumn begins.
What is confirmed
- The FDA approved updated COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax-Sanofi for the 2026-27 season.
- Moderna's approved vaccines include Spikevax and mNEXSPIKE.
- Sanofi's approved vaccine is Nuvaxovid.
- Approvals cover adults aged 65 and older and younger people with underlying health conditions.
- The vaccines target the XFG Stratus variant.
Still unconfirmed
- Insurance coverage for people not in high-risk categories is currently uncertain.
- Bexar County hospitals are seeing more COVID-19 cases as students return to classrooms.
What to watch next
- Confirmation of insurance coverage for healthy adults under 65
- Distribution timelines for pharmacies and hospitals
confidence 90%Sources used for this update (5)
- www.ad-hoc-news.de — Resilient Sanofi stock rides FDA approval of updated COVID vaccine
- www.straitstimes.com — Success after a century of failures: Inside Moderna and Merck’s cancer vaccine breakthrough
- www.ad-hoc-news.de — BioNTech's Monotherapy Setback Puts Platform Strategy in the Spotlight
- www.ksat.com — COVID-19 is back on the rise in Bexar County. Here's what you need to know.
- uk.finance.yahoo.com — What Do Moderna (MRNA) FDA Vaccine Approvals Mean For Its Respiratory Push?
-
FDA approves updated Covid-19 vaccines for 2026-27 season
The FDA has approved updated Covid-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax-Sanofi for the 2026-27 season to target the dominant XFG Stratus variant. The decision allows manufacturers to begin shipping doses, which are expected to arrive at pharmacies and hospitals within days. Current approvals specifically cover adults aged 65 and older and younger individuals with underlying health conditions. While the shots target the latest strain as cases rise, uncertainty remains regarding insurance coverage for those who do not fall into these high-risk categories.
Why it matters
These updates align with the annual cycle of adjusting vaccine formulas to match circulating strains of the virus. The XFG variant has become the dominant strain, necessitating a revised formula to maintain efficacy. This rollout occurs amid a reported increase in Covid-19 cases.
What is confirmed
- The FDA approved updated Covid-19 vaccines for the 2026-27 season.
- The updated vaccines target the dominant XFG variant, also referred to as Stratus.
- Approved manufacturers include Moderna, Pfizer-BioNTech, and Novavax-Sanofi.
- Moderna received approval for updated Spikevax and mNEXSPIKE formulas on August 27, 2026.
Still unconfirmed
- Doses are approved for adults 65 and older and younger people with underlying conditions, but insurance coverage for others is unclear.
What to watch next
- Clarification on insurance coverage for healthy adults under 65
- Official rollout dates for pharmacy and hospital distribution
confidence 95%Sources used for this update (15)
- The New York Times — What to Know About New Covid Vaccines for Fall 2026
- The Washington Post — FDA just approved updated covid shots. Here’s what to know as cases rise.
- Reuters — US FDA approves updated COVID vaccines for 2026-27 season
- CNN — FDA approves updated Covid-19 vaccines
- KATU — FDA approves updated COVID-19 vaccines from Pfizer & Moderna, companies say
- The Guardian — FDA approves updated Covid-19 vaccines for dominant XFG variant
- www.yahoo.com — The FDA just approved this year’s Covid vaccines - here’s what you need to know about the shots
- abcnews.com — FDA approves updated COVID vaccines. Here's what you need to know
- finance.yahoo.com — Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
- www.deseret.com — Updated COVID shots are approved. Getting one may not be simple
- www.theguardian.com — FDA approves updated Covid-19 vaccines for dominant XFG variant
- www.aol.com — Everything you need to know about updated COVID vaccines following FDA approval
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community